Background For more than a decade, guidelines have recommended a limited 3 months of
anticoagulation for the treatment of provoked venous thromboembolism (VTE). How closely …

Background There are limited data assessing the risk for bleeding on anticoagulation
therapy beyond the acute phase in patients with venous thromboembolism (VTE). The …

ContextPatients with venous thromboembolism (VTE) are susceptible to recurrent events,
but whether prolonging anticoagulation is warranted in patients with VTE remains …

Background In patients with unprovoked venous thromboembolism (VTE), anticoagulant
treatment duration should be decided by weighing bleeding risk versus risk of recurrent VTE …

Whether to continue oral anticoagulant therapy indefinitely after completing 3 to 6months of
oral anticoagulant therapy for “unprovoked” venous thromboembolism (VTE), is one of the …

Anticoagulation therapy is the first line and drug of choice for both the treatment and
prophylaxis of venous thromboembolism (deep vein thrombosis and/or pulmonary …

Background Clinical guidelines recommend parenteral anticoagulation therapy with an early
initiation of warfarin therapy for the treatment of patients with acute venous …

Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …

Background The long-term risk of major bleeding after discontinuing anticoagulant therapy
for a first unprovoked venous thromboembolism (VTE) is uncertain. Objectives To determine …

Background The optimal duration of anticoagulation after a first unprovoked venous
thromboembolism (VTE) remains controversial. Deciding to stop or continue anticoagulant …